Moderna tells Reuters will appeal European Patent Office decision

The European Patent Office declared a contested mRNA patent owned by Moderna (MRNA) invalid, handing a win to BioNTech (BNTX) and its partner Pfizer (PFE), Ludwig Burger and Patricia Weiss report, citing a statement from the European Patent Office. Moderna told Reuters that it disagreed with the office’s decision and would lodge an appeal. Shares of Moderna are down 2% to $77.08 in morning trading.